Aptose Biosciences Inc. (TSE:APS – Free Report) (NASDAQ:APTO) – Investment analysts at HC Wainwright issued their FY2024 EPS estimates for Aptose Biosciences in a research report issued to clients and investors on Wednesday, November 20th. HC Wainwright analyst J. Pantginis anticipates that the biotechnology company will earn ($2.51) per share for the year. The consensus estimate for Aptose Biosciences’ current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for Aptose Biosciences’ Q4 2024 earnings at ($0.49) EPS.
Aptose Biosciences Stock Down 20.6 %
Aptose Biosciences stock opened at C$0.27 on Monday. The company has a debt-to-equity ratio of 670.80, a current ratio of 0.80 and a quick ratio of 5.41. The company’s 50-day moving average is C$0.51 and its 200-day moving average is C$0.84. The firm has a market capitalization of C$4.89 million, a PE ratio of -0.05 and a beta of 1.36. Aptose Biosciences has a fifty-two week low of C$0.19 and a fifty-two week high of C$3.90.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Read More
- Five stocks we like better than Aptose Biosciences
- What Do S&P 500 Stocks Tell Investors About the Market?
- Disney’s Magic Strategy: Reinventing the House of Mouse
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Volatility in Semis? 3 Stable Alternatives to NVIDIA and SMCI
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
